Overview

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai YingLi Pharmaceutical Co. Ltd.